Summary:
In patients with diabetic peripheral neuropathy, the addition of empagliflozin 10 mg daily significantly reduced HbA1c, fasting blood glucose, and serum creatinine levels, while improving nerve conduction velocity and eGFR compared to a placebo group continuing their existing diabetes regimen, though it was associated with no reported significant adverse effects in this study.
| PICO | Description |
|---|---|
| Population | Adult patients diagnosed with type 2 diabetes and confirmed diabetic peripheral neuropathy based on the Michigan Neuropathy Screening Instrument. |
| Intervention | Addition of empagliflozin 10 mg once daily to the patients’ existing diabetes treatment regimen for 20 weeks. |
| Comparison | Placebo added to the current diabetes regimen over the same 20-week period. |
| Outcome | The treatment group showed significant improvements in glycemic control (HbA1c and fasting blood glucose), renal function (lower serum creatinine, higher eGFR), and neurological outcomes (increased nerve conduction velocity and reduced latency). No significant difference in amplitude or clinical exam scores was observed. No major side effects were reported. |
Source: Vafaeinasab, Mohammadreza, et al. “The Comparison of the Effect of Adding Empagliflozin to the Medication Regimen on Peripheral Neuropathy in Patients With Type II Diabetes: A Double Blind Randomised Clinical Trial.” Endocrinol Diabetes Metab. Read article here.
